Disc Medicine, Inc 8-K, filed Feb 27, 2026
Disc Medicine, Inc. (IRON)
About this 8-K
Disc Medicine, Inc filed this 8-K on February 27, 2026, reporting on events of February 26, 2026.
Items reported
- Item 2.05: Exit or restructuring costs
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
(Exact name of Registrant as Specified in Its Charter)
(State or Other Jurisdiction |
(Commission File Number) |
(IRS Employer |
||
|
|
|
|
|
|
||||
|
||||
(Address of Principal Executive Offices) |
|
(Zip Code) |
||
Registrant’s Telephone Number, Including Area Code: |
|
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of the Act:
|
|
Trading |
|
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.05 Costs Associated with Exit or Disposal Activities.
On February 26, 2026, the board of directors of Disc Medicine, Inc. (the “Company”) approved, and management began implementing, a restructuring plan (the “Restructuring Plan”) to better align the Company’s workforce with its near-term strategic priorities following the receipt of a complete response letter from the U.S. Food and Drug Administration (“FDA”) on February 13, 2026 with respect to the Company’s New Drug Application for bitopertin for the treatment of erythropoietic protoporphyria and X-linked protoporphyria. Under the Restructuring Plan, the Company is reducing its workforce by approximately 20%. This reduction in staff primarily reflects focused workforce reductions among the Company’s commercial functions and certain supporting functions. The Company expects to complete the implementation of the Restructuring Plan in the second quarter of 2026.
The Company expects that it will incur aggregate charges of approximately $2.0 million in connection with the Restructuring Plan, consisting primarily of severance costs, which will be recorded primarily in the first quarter of 2026. The costs that the Company expects to incur in connection with the Restructuring Plan are subject to a number of assumptions, and actual results may differ materially. The Company may also incur additional costs not currently contemplated due to events that may occur as a result of, or that are associated with, the Restructuring Plan.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
DISC MEDICINE, INC. |
|
|
|
|
Date: |
February 27, 2026 |
By: |
/s/ John Quisel, J.D., Ph.D. |
|
|
|
Name: John Quisel, J.D., Ph.D. |